Addition of enfuvirtide: is it worth it in advanced HIV?

July 2005
PharmacoEconomics & Outcomes News;7/2/2005, Issue 481, p10
Presents the results of a study on the effectiveness of enfuvirtide treatment in patients with HIV infection. Projected quality-adjusted life expectancy (QALY) for patients who received optimized therapy; Cost effectiveness of enfuvirtide plus optimized therapy per QALY.


Related Articles

  • Tipranavir cost effective in treatment-experienced HIV.  // PharmacoEconomics & Outcomes News;7/15/2006, Issue 507, p8 

    Discusses research being done on the cost effectiveness of tipranavir for treatment-experienced patients with HIV infections. Reference to a study by K. N. Simpson et al, published in the May to June 2006 issue of "Value in Health"; Range of the incremental cost-effectiveness ratio for...

  • Cost-Effectiveness of HIV Treatment in Resource-Poor Settings – The Case of Côte d'Ivoire. Goldie, Sue J.; Yazdanpanah, Yazdan; Losina, Elena; Weinstein, Milton C.; Anglaret, Xavier; Walensky, Rochelle P.; Hsu, Heather E.; Kimmel, April; Holmes, Charles; Kaplan, Jonathan E.; Freedberg, Kenneth A. // New England Journal of Medicine;9/14/2006, Vol. 355 Issue 11, p1141 

    Background: As antiretroviral therapy is increasingly used in settings with limited resources, key questions about the timing of treatment and use of diagnostic tests to guide clinical decisions must be addressed. Methods: We assessed the cost-effectiveness of treatment strategies for a cohort...

  • Cost-Effectiveness of an Intervention to Reduce HIV/STI Incidence and Promote Condom Use among Female Sex Workers in the Mexico--US Border Region. Burgos, José L.; Gaebler, Julia A.; Strathdee, Steffanie A.; Lozada, Remedios; Staines, Hugo; Patterson, Thomas L. // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    Background: Previous research demonstrated efficacy of a brief behavioral intervention to reduce incidence of HIV and sexually transmitted infections (STIs) among female sex workers (FSWs) in Tijuana and Ciudad Juarez, Mexico, cities on Mexico's border with the US. We assessed this...

  • Routine HIV Screening in France: Clinical Impact and Cost-Effectiveness. Yazdanpanah, Yazdan; Sloan, Caroline E.; Charlois-Ou, Cécile; Le Vu, Stéphane; Semaille, Caroline; Costagliola, Dominique; Pillonel, Josiane; Poullié, Anne-Isabelle; Scemama, Olivier; Deuffic-Burban, Sylvie; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.; Paltiel, A. David // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: In France, roughly 40,000 HIV-infected persons are unaware of their HIV infection. Although previous studies have evaluated the cost-effectiveness of routine HIV screening in the United States, differences in both the epidemiology of infection and HIV testing behaviors warrant a...

  • Taking Antiretroviral Therapy for HIV Infection. Laws, M. Barton; Wilson, Ira B.; Bowser, Diana M.; Kerr, Sarah E. // JGIM: Journal of General Internal Medicine;Dec2000, Vol. 15 Issue 12, p848 

    OBJECTIVE: To describe how people with HIV understand and experience the problem of adhering to antiretroviral medication regimens. DESIGN: We performed a qualitative study based on interviews with HIV-infected patients, including 46 clients of AIDS service organizations, who were sampled...

  • Prevalence of concomitant medications in older HIV+ patients and comparison with general population. Gimeno-Gracia, Mercedes; Crusells-Canales, María José; Javier Armesto-Gómez, Francisco; Rabanaque-Hernández, María José // HIV Clinical Trials;05/01/2015, p117 

    Objective: The increasing population of human immunodeficiency virus (HIV)-infected elderly patients results in a higher number of comorbidities and greater incidence of polypharmacy in addition to antiretroviral therapy (ART). The aim of this study is to describe the use of concomitant...

  • "Significant cost savings" accrued with discontinuation of HAART.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p9 

    Discusses research being done on cost saving and clinical outcome associated with the discontinuation of therapy in HIV patients. Reference to a study by P. Keiser and colleagues, presented at the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment in July 2005;...

  • Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ⩽100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings. Meya, David B.; Manabe, Yukari C.; Castelnuovo, Barbara; Cook, Bethany A.; Elbireer, Ali M.; Kambugu, Andrew; Kamya, Moses R.; Bohjanen, Paul R.; Boulware, David R. // Clinical Infectious Diseases;8/15/2010, Vol. 51 Issue 4, p448 

    Background. Cryptococcal meningitis (CM) remains a common AIDS-defining illness in Africa and Asia. Subclinical cryptococcal antigenemia is frequently unmasked with antiretroviral therapy (ART).We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify...

  • The Cost-Effectiveness of Monitoring Strategies for Antiretroviral Therapy of HIV Infected Patients in Resource-Limited Settings: Software Tool. Estill, Janne; Salazar-Vizcaya, Luisa; Blaser, Nello; Egger, Matthias; Keiser, Olivia // PLoS ONE;Mar2015, Vol. 10 Issue 3, p1 

    Background: The cost-effectiveness of routine viral load (VL) monitoring of HIV-infected patients on antiretroviral therapy (ART) depends on various factors that differ between settings and across time. Low-cost point-of-care (POC) tests for VL are in development and may make routine VL...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics